Department of Ophthalmology, Indiana University School of Medicine, Indianapolis, IN, United States.
Electrical and Computer Engineering Technology, Purdue University, West Lafayette, IN, United States.
Surv Ophthalmol. 2024 Nov-Dec;69(6):967-983. doi: 10.1016/j.survophthal.2024.07.002. Epub 2024 Jul 8.
Ophthalmic treatment demands precision and consistency in delivering therapeutic agents over extended periods to address many conditions, from common eye disorders to complex diseases. This diversity necessitates a range of delivery strategies, each tailored to specific needs. We delve into various delivery cargos that are pivotal in ophthalmic care. These cargos encompass biodegradable implants that gradually release medication, nonbiodegradable implants for sustained drug delivery, refillable tools allowing flexibility in treatment, hydrogels capable of retaining substances while maintaining ocular comfort, and advanced nanotechnology devices that precisely target eye tissues. Within each cargo category, we explore cutting-edge research-level approaches and FDA-approved methods, providing a thorough overview of the current state of ophthalmic drug delivery. In particular, our focus on nanotechnology reveals the promising potential for gene delivery, cell therapy administration, and the implantation of active devices directly into the retina. These advancements hold the key to more effective, personalized, and minimally- invasive ophthalmic treatments, revolutionizing the field of eye care.
眼科治疗需要在较长时间内精确且一致地输送治疗剂,以解决从常见眼病到复杂疾病等多种病症。这种多样性需要一系列的输送策略,每种策略都针对特定的需求进行了定制。我们深入探讨了在眼科护理中至关重要的各种输送载体。这些载体包括可生物降解的植入物,它们可逐渐释放药物;不可生物降解的植入物,用于持续药物输送;可再填充工具,在治疗中具有灵活性;水凝胶可在保持眼部舒适度的同时保留物质;以及先进的纳米技术设备,可精确靶向眼部组织。在每个载体类别中,我们探索了处于研究级别的前沿方法和获得 FDA 批准的方法,全面概述了当前的眼科药物输送现状。特别是,我们对纳米技术的关注揭示了基因输送、细胞疗法管理以及将活性设备直接植入视网膜的有前途的潜力。这些进展为更有效、个性化和微创的眼科治疗提供了关键,彻底改变了眼科护理领域。